SINGAPORE, Jan. 13, 2026 — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”)—a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China.
Strategic Investment and Facility Expansion Plan
Under the agreement’s terms, EUDA expects to invest up to RMB 6 million in two tranches: an initial RMB 1 million tranche and a second RMB 5 million tranche. This is subject to completing due diligence, securing regulatory approvals and executing definitive agreements.
Shenzhen Inno will use the capital to upgrade its cGMP facility in Shenzhen, turning it into a state-of-the-art production and innovation center for stem cell treatments. The facility is set to act as a core technology and operating hub for EUDA’s China strategy—anchoring its regenerative medicine capabilities, supporting international collaborations and providing a replicable platform to expand into more cities and markets.
The investment takes the form of a convertible loan note that gives EUDA the option to convert it into an equity interest in Shenzhen Inno. The resulting ownership percentage will be determined at conversion based on valuation and definitive documentation. The note is expected to carry a 6% annual interest rate, payable semi-annually, and may be redeemed with accrued interest if not converted—all subject to final terms.
Shenzhen Inno operates a stem cell technology and therapy platform focused on advanced human cell processing, quality controlled cell culture, precision biological workflows and regulated laboratory operations. It supports programs for natural killer cell, gamma delta T cell, cytokine induced killer cell, mesenchymal stem cell, induced pluripotent stem cell and organoid based therapies. The platform integrates biological processing infrastructure, quality and compliance systems, and scalable operating processes designed to support both clinical and research applications.
Shenzhen Inno – Strong Institutional Backing
In August 2017, HSG Capital Group (“HSG”)—formerly known as Sequoia Capital China, a leading international venture capital and private equity firm—made a strategic investment of approximately US$8 million in Shenzhen Inno. This capital provided early institutional validation of its scientific platform, regulatory foundation and long-term commercial potential, while supporting the development of its laboratory infrastructure, quality systems and core technical team.
Mr Alfred Lim, Chief Executive Officer of EUDA, commented:
“This agreement reflects our disciplined approach to building long-term stem cell therapy platforms. By supporting the upgrade and expansion of a high-quality platform through a phased, flexible investment structure, we can validate execution, align our strategies and lay the groundwork for deeper ownership and integration over time. This positions EUDA not just as a healthcare provider, but as a vertically integrated platform with technology, infrastructure and operational depth.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia, focused on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region—a region undergoing significant demographic shifts as more than 30% of its population ages rapidly. By offering innovative, accessible and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
This document may contain forward-looking statements about risks and uncertainties. These statements usually use forward-looking words like “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose”—and variations of these words or similar expressions (or their negative versions). These forward-looking statements are not guarantees of future performance, conditions or results. They involve many known and unknown risks, uncertainties, assumptions and other key factors—most of which are outside EUDA’s control—that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on these statements, which apply only as of the document’s publication date. The Company does not undertake any obligation to update or revise any forward-looking statements—whether due to new information, future events or otherwise—except as required by law.
Christensen Advisory
Christian Arnell
Phone: + 852 9040 0621
Email:
